Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, ...
The long-running “Du More” motif for Sanofi and Regeneron’s immunology blockbuster Dupixent is looking to make a splash with its first new commercial of 2023. In the 60-second spot, “It's Possible: ...
Dupixent is a blockbuster immunology drug that just keeps delivering for Sanofi and Regeneron, so it’s no surprise that the “franchise in a therapy” has got a new set of ads. Sanofi and Regeneron, ...
Asthma New analyses evaluate the efficacy of Dupixent in moderate-to-severe asthma patients with an allergic phenotype over the long-term, as well as difficult-to-treat patients. Analyses also explore ...
24 abstracts, including 1 oral presentation and 4 late-breaking posters on Dupixent, to showcase new clinical and real-world analyses in chronic obstructive pulmonary disease (COPD) and asthma COPD ...
New results from a Dupixent (dupilumab) phase 3 open-label extension trial showed that the safety and efficacy profile observed in previous Dupixent trials were maintained for up to three years in ...
Shares of drugmakers Sanofi and Regeneron both jumped more than 6% after they released data on a jointly developed drug that shows promise in treating COPD. The drug is already approved for asthma and ...
The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 VOYAGE trial. The Food and Drug Administration (FDA) has expanded the approval of Dupixent ® (dupilumab) to ...
Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter The RAPID registry from Regeneron and Sanofi tracks how real patients with asthma start ...
The European Commission (EC) has expanded the marketing authorization for Dupixent (dupilumab) for use in children aged 6 to 11 years as an add-on maintenance treatment for severe asthma with type 2 ...
Asthma impacts over 300 million people worldwide, leading to chronic and acute inflammation of the air passages of both children and adults. It includes a complex array of inflammatory processes of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results